By Fineline Cube 
Broncus Medical (HKG: 2216) announced that its wholly‑owned subsidiary, Broncus China Holding Corporation, has agreed to acquire 157,800 Series B Preferred Shares of Valgen Holding Corporation from Venus Medtech (Hangzhou) Inc. (HKG: 2500) for US$15 million cash, representing 1.05% of Valgen’s issued share capital. Upon completion, Venus Medtech will exit its position in Valgen Holding.
Transaction Overview
| Item | Detail |
|---|---|
| Acquirer | Broncus Medical (2216.HK) via Broncus China Holding |
| Seller | Venus Medtech (Hangzhou) Inc. (2500.HK) |
| Target | Valgen Holding Corporation |
| Asset | 157,800 Series B Preferred Shares (1.05% stake) |
| Consideration | US$15 million cash |
| Transaction Date | 29 Dec 2025 |
| Post‑Transaction | Venus Medtech holds 0% in Valgen |
Company Profiles
| Company | Focus Area | Core Competency | Market Position |
|---|---|---|---|
| Broncus Medical | Interventional pulmonology | Medical devices & consumables for lung disease | Leading China player |
| Valgen Holding | Structural heart disease | Interventional technologies for cardiac conditions | R&D‑stage innovator |
| Venus Medtech | Cardiovascular devices | Investment & portfolio management | Exiting Valgen position |
Strategic Synergy Analysis
Rationale for Acquisition:
- Cardiopulmonary Integration: Structural heart disease and pulmonary diseases share clinical correlations; combined expertise enables integrated diagnosis and treatment
- Technology Transfer: Valgen’s interventional technologies can be adapted for pulmonary applications, accelerating Broncus’s R&D pipeline
- Cross‑Specialty Platform: Both fields utilize catheter‑based interventions; knowledge sharing reduces development risk and expands addressable market
Market Opportunity
| Segment | China Market Size (2025) | Growth Driver | Broncus‑Valgen Synergy |
|---|---|---|---|
| Interventional Pulmonology | ¥8.5 billion (US$1.2 B) | COPD, lung cancer screening | Apply cardiac navigation to lung procedures |
| Structural Heart Disease | ¥12.0 billion (US$1.7 B) | Aging population, TAVR growth | Leverage lung imaging for cardiac interventions |
| Combined Cardiopulmonary | ¥20.5 billion (US$2.9 B) | Integrated care models | Cross‑pollination of interventional tech |
Financial Implications
- Investment Size: US$15 million represents 2.1% of Broncus Medical’s cash position (HK$5.6 billion as of H1 2025)
- Valuation: Implies US$1.43 billion post‑money valuation for Valgen Holding
- Accounting Treatment: Minority stake to be recorded as long‑term equity investment
- Earnings Impact: No immediate P&L impact; potential for R&D cost synergies of ¥30‑50 million annually by 2027
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Broncus Medical’s strategic synergies, Valgen Holding’s technology applications, and potential cost savings. Actual results may differ due to integration challenges, clinical development risks, and competitive dynamics in interventional cardiopulmonary markets.-Fineline Info & Tech